Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Saved in:
Bibliographic Details
Title: Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Authors: Janani L; Imperial Clinical Trials Unit, Imperial College London, London, UK., Munro APS; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Wright A; Imperial Clinical Trials Unit, Imperial College London, London, UK., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Babbage G; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Baxter D; Stockport NHS Foundation Trust, Stockport, UK., Bawa T; Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK., Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Bula M; NIHR Liverpool Clinical Research Facility, Liverpool, UK., Cathie K; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Chatterjee K; NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Cosgrove C; Institute of Infection and Immunity & Vaccine Institute, City St George's, University of London, UK; St George's University Hospitals NHS Foundation Trust, London, UK., Enever Y; PHARMExcel, Welwyn Garden City, Hertfordshire, UK., Galiza E; Institute of Infection and Immunity & Vaccine Institute, City St George's, University of London, UK; St George's University Hospitals NHS Foundation Trust, London, UK., Goodman AL; Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK., Green CA; NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Harris M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Hicks A; Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Jones CE; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Kanji N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., van der Klaauw AA; Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK., Llewelyn MJ; University Hospitals Sussex NHS Foundation Trust, Brighton, UK., Mansfield R; Dorset Research Hub, Bournemouth, UK., McGregor AC; Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK., Minassian AM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Moore P; The Adam Practice, Poole, UK., Mujadidi YF; NIHR Oxford Biomedical Research Centre, Oxford, UK., Belhadef HT; NIHR Oxford Biomedical Research Centre, Oxford, UK., Holliday K; NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK., Osanlou O; Public Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK., Osanlou R; University of Liverpool, Liverpool, UK., Pacurar M; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Palfreeman A; University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK., Regan K; Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK., Saich S; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Saralaya D; Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK., Sharma S; University Hospitals Sussex NHS Foundation Trust, Brighton, UK., Sheridan R; Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK., Stokes M; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Thomson EC; Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; MRC University of Glasgow Centre for Virus Research, Glasgow, UK., Todd S; Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK., Twelves C; NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK., Wright D; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Charlton S; UK Health Security Agency, Porton Down, UK., Hallis B; UK Health Security Agency, Porton Down, UK., Ramsay M; UK Health Security Agency, Colindale, London, UK., Andrews N; UK Health Security Agency, Colindale, London, UK., Nguyen-Van-Tam JS; Lifespan and Population Health Unit, University of Nottingham School of Medicine, UK., Cornelius V; Imperial Clinical Trials Unit, Imperial College London, London, UK., Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK., Heath PT; Institute of Infection and Immunity & Vaccine Institute, City St George's, University of London, UK; St George's University Hospitals NHS Foundation Trust, London, UK., Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: xinxue.liu@paediatrics.ox.ac.uk., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Electronic address: s.faust@soton.ac.uk.
Corporate Authors: COV-BOOST study group
Source: The Journal of infection [J Infect] 2025 Sep; Vol. 91 (3), pp. 106576. Date of Electronic Publication: 2025 Aug 07.
Publication Type: Journal Article; Clinical Trial, Phase III
Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-2742
DOI:10.1016/j.jinf.2025.106576